BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation

BACKGROUND: Mutated epidermal growth factor receptor (EGFR) is one of the most successful targets in cancer targeted therapy. While this treatment has benefited many patients with an activating EGFR mutation (EGFRm), almost all those who initially benefited will eventually develop acquired drug resi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Biosci
Main Authors: Zhan, Yihong, Wang, Yue, Qi, Miao, Liang, Panpan, Ma, Yu, Li, Ting, Li, Hui, Dai, Congmei, An, Zhifeng, Qi, Yitao, Wu, Hongmei, Shao, Huanjie
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6651933/
https://ncbi.nlm.nih.gov/pubmed/31367332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13578-019-0322-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados